Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Erste Asset Management GmbH boosted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 55.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 73,000 shares of the biotechnology company’s stock after buying an additional 26,000 shares during the quarter. Erste Asset Management GmbH owned approximately 0.05% of Arrowhead Pharmaceuticals worth $2,466,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ARWR. Marex Group plc bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth approximately $576,000. Nordea Investment Management AB grew its holdings in shares of Arrowhead Pharmaceuticals by 74.5% during the 3rd quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock worth $12,661,000 after purchasing an additional 158,937 shares in the last quarter. Marshall Wace LLP boosted its stake in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after buying an additional 2,096,238 shares in the last quarter. HBK Sorce Advisory LLC bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at about $2,823,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $287,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Mauro Ferrari sold 7,530 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the sale, the director directly owned 69,053 shares of the company’s stock, valued at approximately $4,833,710. This trade represents a 9.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer owned 474,908 shares of the company’s stock, valued at $29,971,443.88. This trade represents a 9.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 502,086 shares of company stock worth $33,109,648 in the last ninety days. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $63.27 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76. The firm has a market capitalization of $8.86 billion, a price-to-earnings ratio of 41.35 and a beta of 1.21. The stock’s 50 day moving average price is $66.12 and its two-hundred day moving average price is $48.55. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. During the same period in the prior year, the business earned ($1.39) EPS. The company’s revenue for the quarter was up 10461.3% compared to the same quarter last year. On average, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARWR has been the subject of a number of recent analyst reports. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. The Goldman Sachs Group raised their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Finally, Morgan Stanley raised their target price on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.